Trial Profile

A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 With Peginterferon Alfa 2a and Ribavirin (RBV) in Treatment-Naive Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ledipasvir (Primary) ; Vedroprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use
Sponsors Gilead Sciences

24 Dec 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
28 Apr 2013 Interim results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
23 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com